A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

NCT06192108 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

962

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Orforglipron
DRUG: Dapagliflozin

Sponsor

Eli Lilly and Company